Zhao Li1, Chaohsiung Hsu2, Chih-Wei Lai1, Matthew Rochefort3, Yu-Hao Chen2, James S. Tomlinson3, Lian-Pin Hwang2, Vay Liang W. Go4, Yung-Ya Lin1
1Chemistry and Biochemistry, UCLA, Los Angeles, CA, United States; 2Chemistry, National Taiwan University, Taipei, Taiwan; 3Surgical Oncology, UCLA, Los Angeles, CA, United States; 4UCLA Center for Excellence in Pancreatic Diseases, UCLA, Los Angeles, CA, United States
Early detection of pancreatic cancers using enhanced MRI techniques increases not only the treatment options available, but also the patients survival rate. This can be achieved with antibody-conjugated superparamagnetic iron oxide (SPIO) nanoparticles capable of binding to early stage pancreatic cancer cells to improve imaging specificity and innovation methods that can sensitively detect SPIO to improve imaging sensitivity. The enhanced contrast from SPIO can then be used to visually assess the distribution and magnitude of SPIO-targeted tumor cells. In vivo subcutaneous and orthotopic xenografts mouse models validated the superior contrast/sensitivity and robustness of this approach towards early pancreatic cancers detection.